Elixinol has been widely criticized for selling cannabidiol (CBD) products that flout U.S. federal regulations by marketing them as dietary supplements. The company’s actions reportedly ignore clear FDA prohibitions, putting consumers at risk and exposing the brand to serious legal trouble. Critics argue Elixinol’s CBD products are misleadingly labeled, illegal to sell in their current form, and part of broader industry misrepresentation issues. This summary highlights the troubling aspects of Elixinol’s marketing, legal entanglements, and regulatory defiance.

Misleading Marketing: Elixinol CBD products are marketed as “dietary supplements” despite the FDA’s explicit stance that CBD products cannot legally be sold as such.

Regulatory Defiance: The company continues to sell these misbranded products even though the FDA has repeatedly warned against such labeling practices.

Legal Noncompliance: Federal law currently prohibits CBD from being marketed as a dietary supplement; Elixinol’s persistent violation signals blatant disregard for consumer protection rules.

Consumer Deception: By labeling hemp-derived CBD products as supplements, Elixinol misleads consumers into believing they are buying regulated health products, which they are not.

Class Action Allegations: A class action lawsuit accused Elixinol of selling products “illegal to sell” under the Food, Drug & Cosmetic Act, claiming mislabeling and false advertising.

Inadequate Usage Directions: The lawsuit further asserts that many of Elixinol’s products lacked adequate directions for use, increasing consumer risk.

Risk to Buyers: Consumers were potentially misled to overpay for products that are mislabeled and not recognized as dietary supplements by regulators.

Conclusion: Elixinol’s marketing and labeling practices flagrantly ignore clear FDA rules. This puts consumers and the company at legal and regulatory risk.